NASDAQ:DERM Journey Medical (DERM) Stock Price, News & Analysis $7.57 +0.27 (+3.70%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.54 -0.03 (-0.40%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Journey Medical Stock (NASDAQ:DERM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Journey Medical alerts:Sign Up Key Stats Today's Range$7.25▼$7.7050-Day Range$6.31▼$7.8152-Week Range$3.54▼$8.25Volume71,427 shsAverage Volume112,276 shsMarket Capitalization$176.38 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingBuy Company Overview Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc. Read More Journey Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreDERM MarketRank™: Journey Medical scored higher than 38% of companies evaluated by MarketBeat, and ranked 749th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJourney Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJourney Medical has only been the subject of 1 research reports in the past 90 days.Read more about Journey Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Journey Medical are expected to grow in the coming year, from ($1.02) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Journey Medical is -19.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Journey Medical is -19.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJourney Medical has a P/B Ratio of 8.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Journey Medical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.54% of the float of Journey Medical has been sold short.Short Interest Ratio / Days to CoverJourney Medical has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Journey Medical has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJourney Medical does not currently pay a dividend.Dividend GrowthJourney Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.54% of the float of Journey Medical has been sold short.Short Interest Ratio / Days to CoverJourney Medical has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Journey Medical has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.52 News SentimentJourney Medical has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Journey Medical this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Journey Medical insiders have not sold or bought any company stock.Percentage Held by Insiders15.03% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.25% of the stock of Journey Medical is held by institutions.Read more about Journey Medical's insider trading history. Receive DERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Journey Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address DERM Stock News HeadlinesJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | DERM Stock NewsAugust 7 at 9:22 AM | gurufocus.comJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11August 7 at 9:22 AM | gurufocus.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!). | Weiss Ratings (Ad)Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11August 7 at 8:30 AM | globenewswire.comJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | globenewswire.comJourney Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseAugust 4, 2025 | msn.comQ2 Earnings Forecast for Journey Medical Issued By B. RileyAugust 2, 2025 | americanbankingnews.comJourney Medical Corporation Reports Increase in Payer Coverage for Emrosi™ to 65% of Commercial Lives, Supporting Growing Prescription DemandJuly 14, 2025 | quiverquant.comQSee More Headlines DERM Stock Analysis - Frequently Asked Questions How have DERM shares performed this year? Journey Medical's stock was trading at $3.91 at the start of the year. Since then, DERM shares have increased by 93.6% and is now trading at $7.57. How were Journey Medical's earnings last quarter? Journey Medical Corporation (NASDAQ:DERM) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The company had revenue of $13.14 million for the quarter, compared to the consensus estimate of $12.05 million. Journey Medical had a negative net margin of 14.76% and a negative trailing twelve-month return on equity of 52.03%. Read the conference call transcript. When did Journey Medical IPO? Journey Medical (DERM) raised $39 million in an initial public offering (IPO) on Friday, November 12th 2021. The company issued 3,520,000 shares at $10.00-$12.00 per share. Who are Journey Medical's major shareholders? Journey Medical's top institutional investors include Geode Capital Management LLC (1.13%), Envestnet Asset Management Inc. (0.30%), Atria Investments Inc (0.16%) and Creative Planning (0.14%). Insiders that own company stock include Claude Maraoui, Ramsey Alloush, Lindsay A Md Rosenwald, Justin Adam Smith and Joseph Benesch. View institutional ownership trends. How do I buy shares of Journey Medical? Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Journey Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Journey Medical investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Adobe (ADBE) and AppLovin (APP). Company Calendar Last Earnings5/14/2025Today8/09/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DERM Previous SymbolNASDAQ:DERM CIK1867066 Webjourneymedicalcorp.com Phone480-434-6670FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Journey Medical$9.50 High Price Target$10.50 Low Price Target$9.00 Potential Upside/Downside+25.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.67 million Net Margins-14.76% Pretax Margin-14.65% Return on Equity-52.03% Return on Assets-11.28% Debt Debt-to-Equity Ratio1.07 Current Ratio1.34 Quick Ratio1.03 Sales & Book Value Annual Sales$56.13 million Price / Sales3.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book8.32Miscellaneous Outstanding Shares23,300,000Free Float19,795,000Market Cap$176.38 million OptionableN/A Beta0.80 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:DERM) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.